# US 2025/0375539 A1 · Compositions of dispersed systems for biomedical applications, process for their preparation and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375539 A1
- Document ID: US20250375539A1
- Status: Published application
- Kind: A1
- Application number: 18/856,605
- Filed: 2023-04-13
- Published: 2025-12-11
- Earliest claimed: 2022-04-14
- Assignees: Superbranche; Centre National De La Recherche Scientifique
- Applicants: Superbranche; Centre National De La Recherche Scientifique
- Inventors: Delphine FELDER-FLESCH; Benjamin AYELA; Marie Pierre KRAFFT; Da SHI; Hagop ABADIAN; Salima EL-YAHKLIFI
- Web page: https://patentgrep.com/patent/US20250375539A1

## CPC

- A61K 49/226: {Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels}
- A61K 49/223: {Microbubbles, hollow microspheres, free gas bubbles, gas microspheres}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to the use of oligo(ethylene oxide) dendritic molecules for stabilizing fluorocarbon-based nanoemulsions, to fluorocarbon-based nanoemulsions comprising such dendritic molecules and to their uses for biomedical applications, in particular as contrast agents, drug carrier or oxygenating agent.

## Claims

### Claim 1

Use of an oligo(ethylene oxide) dendritic molecule of formula (I) below:
wherein:
R1 is a group selected among:
an alkyl radical having at least 2 carbon atoms or an alkyl radical having at least 2 carbon atoms and comprising a terminal fluorinated group,
a group —OR4 or —COOR4 in which R4 represents a linear alkyl radical having at least 4 carbon atoms or an alkyl radical having at least 2 carbon atoms and comprising a terminal fluorinated group, and
a phosphonate group of the following formula (PG):
in which each of R5 represents a hydrogen atom or a linear alkyl radical having at least 1 carbon atom and the star represents the attachment point of said group of formula (PG) to the phenyl cycle;
each of R2 represents a linear alkyloxy radical having from 1 to 20 carbon atoms;
R3 represents a linear alkyloxy radical having from 1 to 20 carbon atoms, a carboxyl group or a group-COOtBu in which (Bu means ter-butyl;
n is an integer ranging from 1 to 16;
p is an integer ranging from 1 to 16;
m is an integer ranging from 1 to 4, preferably m=1 or 2 and more preferably m=2; and
q is an integer ranging from 1 to 3, with the proviso that when R1 represents a phosphonate group PG, then q=2,
for stabilizing a fluorocarbon-based nanoemulsion consisting of a dispersion of nanodroplets of a liquid fluorocarbon stabilized in a continuous aqueous phase by a thin lipid film present at the interface between said aqueous phase and said liquid fluorocarbon, said lipid film comprising phospholipid(s) and at least one oligo(ethylene oxide) dendron of formula (I).

### Claim 2 (depends on 1)

The use according to claim 1, wherein the oligo(ethylene oxide) dendritic molecule of formula (I) is a compound in which q=2 and R1 represents a phosphonate group of formula (PG) in which each of R5 represents a hydrogen atom or an alkyl group having from 4 to 12 carbon atoms.

### Claim 3 (depends on 2)

The use according to claim 2, wherein said oligo(ethylene oxide) dendritic molecule of formula (I) are grafted on magnetic nanoparticles.

### Claim 4 (depends on 1)

The use according to claim 1, wherein the oligo(ethylene oxide) dendritic molecule of formula (I) is a compound in which q=2 and R1 represents an alkyl group selected among octyl, decanyl, and dodecanyl or a fluorinated group selected among —(CH2)6—CF2CF3 and —(CH2)2—CF(CF3)2.

### Claim 5 (depends on 1)

The use according to claim 1 wherein the oligo(ethylene oxide) dendritic molecule of formula (I) is a compound in which q=2 and R1 represents a group —OR4 or —COOR4 in which R4 represents an alkyl group selected among octyl, decanyl, and dodecanyl or a fluorinated group selected among —(CH2)6—CF2CF3 and —(CH2)2—CF(CF3)2.

### Claim 6 (depends on 1)

The use according to claim 1, wherein the oligo(ethylene oxide) dendritic molecule of formula (I) is a compound in which each of R2 represents a methyloxy group.

### Claim 7 (depends on 1)

The use according to claim 1, wherein the oligo(ethylene oxide) dendritic molecule of formula (I) is a compound in which R3 represents a methyloxy group, a carboxyl group or a group-COOtBu in which (Bu means ter-butyl.

### Claim 8 (depends on 1)

The use according to claim 1, wherein the oligo(ethylene oxide) dendritic molecule of formula (I) is a compound selected among compounds of formulae (I-A) to (I-T) whose significations of R1 to R5, m, n p and q are given in the following Table 1:
TABLE 1
Cpds
R1
R2
R3
R4
R5
n
p
m
q
(I-A)
PG
—OCH3
—OCH3
—
—(CH2)7—CH3
4
4
2
2
(I-B)
PG
—OCH3
—OCH3
—
—(CH2)9—CH3
4
4
2
2
(I-C)
PG
—OCH3
—OCH3
—
—(CH2)11—CH3
4
4
2
2
(I-D)
PG
—OCH3
—COOH
—
—(CH2)7—CH3
4
9
2
2
(I-E)
PG
—OCH3
—COOH
—
—(CH2)9—CH3
4
9
2
2
(I-F)
PG
—OCH3
—COOH
—
—(CH2)11—CH3
4
9
2
2
(I-G)
—(CH2)7—CH3
—OCH3
—COOH
—
—
4
9
2
2
(I-H)
—(CH2)6CF2CF3
—OCH3
—COOH
—
—
4
9
2
2
(I-I)
—(CH2)2CF(CF3)2
—OCH3
—COOH
—
—
4
9
2
2
(I-J)
—COOR4
—OCH3
—COOH
—(CH2)7—CH3
—
4
9
2
2
(I-K)
—COOR4
—OCH3
—COOH
—(CH2)6CF2CF3
—
4
9
2
2
(I-L)
—COOR4
—OCH3
—COOH
—(CH2)2CF(CF3)2
—
4
9
2
2
(I-M)
—OR4
—OCH3
—COOH
—(CH2)7—CH3
—
4
9
2
2
(I-N)
—OR4
—OCH3
—COOH
—(CH2)2CF(CF3)2
—
4
9
2
2
(I-O)
—OR4
—OCH3
—COOH
—(CH2)6CF2CF3
—
4
9
2
2
(I-P)
PG
—OCH3
—COOH
—(CH2)7—CH3
H
4
9
2
2
(I-Q)
PG
—OCH3
—COOtBu
—CH2CH3
4
9
2
2
(I-R)
—COOR4
—OCH3
—COOtBu
—(CH2)7—CH3
—
4
9
2
2
(I-S)
—COOR4
—OCH3
—COOtBu
—(CH2)2CF(CF3)2
—
4
9
2
2
(I-T)
—COOR4
—OCH3
—COOtBu
—(CH2)6CF2CF3
—
4
9
2
2

### Claim 9 (depends on 1)

Fluorocarbon-based nanoemulsion comprising an aqueous continuous phase and a dispersion of nanodroplets consisting of a membrane of a lipid phase encapsulating at least one liquid fluorocarbon, wherein the lipid phase comprises at least one phospholipid and at least one oligo(ethylene oxide) dendritic molecule of formula (I) as defined in claim 1.

### Claim 10 (depends on 9)

The fluorocarbon-based nanoemulsion according to claim 9, wherein the at least one fluorocarbon is chosen among perfluorobutane, perfluoropentane, 2H,3H-perfluoropentane, perfluorohexane, perfluoroheptane, perfluorooctane, perfluorononane, perfluorodecalin, perfluorooctylbromide and perfluorotripropylamine.

### Claim 11 (depends on 9)

The fluorocarbon-based nanoemulsion according to claim 9, wherein the concentration of fluorocarbon varies from 1 to 30% w/w.

### Claim 12 (depends on 9)

The fluorocarbon-based nanoemulsion according to claim 9, wherein the at least one phospholipid is chosen among dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoylphosphatidylcholine.

### Claim 13 (depends on 9)

The fluorocarbon-based nanoemulsion according to claim 9, wherein the concentration of the at least one phospholipid varies from 0.25 to 10% w/w.

### Claim 14 (depends on 9)

The fluorocarbon-based nanoemulsion according to claim 9, wherein the concentration of the oligo(ethylene oxide) dendritic molecule of formula (I) varies from 0.07 to 0.7% w/w.

### Claim 15 (depends on 9)

The fluorocarbon-based nanoemulsion according to claim 9, wherein the phospholipid/oligo(ethylene oxide) dendritic molecule of formula (I) molar ratio varies from about 5:1 to 50:1.

### Claim 16 (depends on 9)

Use of a fluorocarbon-based nanoemulsion as defined in claim 9, as a contrast agent.

### Claim 17 (depends on 9)

A fluorocarbon-based nanoemulsion as defined in claim 9, for its use as drug carrier or as oxygenating agent in a method of treatment by therapy.
